Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

December 03, 2018   |   December 2018 Bond Updates
OSLO, Dec. 3, 2018 /PRNewswire/ -- Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL) Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and...

View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-single-administration-betalutin-r-is-effective-and-well-tolerated-in-r-r-inhl-patients-6-month-follow-up-data-presented-at-ash-841004804.html
 
Related News
Home| About us | Contact us http://www.bondupdatesdailynews.com/